A combination of chemotherapy and immunotherapy has proven promising in treating patients with advanced Hodgkin Lymphoma, and removes the need for radiation therapy in kids. In a new phase 3 clinical trial, 94% of patients receiving the combo treatment were in remission after one year.
Hodgkin Lymphoma is a relatively rare kind of cancer that affects the lymph nodes. It mostly strikes younger people, between the ages of 20 and 40, and can often be treated with chemotherapy or radiation therapy.
Reuters/Ipsos poll: Majority of Republicans believe charges against Trump “Politically Motivated”
A new clinical trial has now investigated adding immunotherapy to the mix. It ran between July 2019 and October 2022 and involved almost 1,000 patients with stage 3 or 4 Hodgkin Lymphoma. The trial compared a standard treatment of chemotherapy with the drug brentuximab vedotin, against a pairing of chemotherapy and an immunotherapy drug called nivolumab.
Read more: New Atlas
